Research in the January 2023 issue of the Journal of the National Comprehensive Cancer Network finds that immunotherapy from PD-1 inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.
A study, conducted by UC Davis Comprehensive Cancer Center researchers, shows an alarming number of California women 65 and older are facing late-stage cervical cancer diagnoses and dying from the disease, despite guidelines that recommend most women stop screening for cervical cancer at this age.
A study led by investigators from the Mass General Cancer Center, a member of Mass General Brigham, in collaboration with researchers at the Massachusetts Institute of Technology, developed and tested an artificial intelligence tool that accurately predicted the risk of lung cancer for individuals with or without a significant smoking history.
Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma animal models dramatically in a study led by a UT Southwestern resident.
Severe inflammation weakens the body’s ability to kill cancerous blood cells in people with acute myeloid leukemia, a study shows.
Afami-cel (afamitresgene autoleucel; formerly ADP-A2M4), an adoptive T-cell receptor therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial led by researchers at MD Anderson Cancer Center.
Results from the first completed clinical trial facilitated and organized by DKMS, the world’s largest stem cell donor center, suggest that adult patients who have relapsed or refractory acute myeloid leukemia should receive stem cell transplantation as soon as possible.
A large study found that expanded Medicaid coverage under the Affordable Care Act leads to better survival outcomes for young adults ages 18-39 newly diagnosed with cancer, particularly those who identified as Hispanic or non-Hispanic Black.
A global, phase III clinical trial evaluating the safety and efficacy of TAVT-45 (abiraterone acetate) granules for oral suspension, an investigational enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer, produced positive topline results.
HERIZON-BTC-01, a pivotal phase IIb, open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers, produced positive topline results.